Age and laterality of children should be considered when determining IOL power

Article

A child's age and laterality are important factors to consider when determining intraocular lens (IOL) power.

A study featured in the British Journal of Ophthalmology has shown that a child's age and laterality are important factors to consider when determining intraocular lens (IOL) power.

A team lead by Dr R. Wolfs, Erasmus University Medical Center, Department of Ophthalmology, The Netherlands, investigated the amount of myopic shift in children after catract surgery with IOL implantation. The children were split into three groups according to their age. Group A consisted of 0–1 year olds, Group B, 1–7 year olds and Group C, 7–18 year olds. Expected myopic shift was calculated using a formula created by multiple regression analysis. Variables linked with a higher prediction area were also calculated.

Children aged 12 months and under presented with higher myopic shifts and a bigger mean rate of refractive change per year. Higher myopic shifts were also found in children with unilateral cataract. Group A experienced a significantly higher absolute prediction error compared to Group B and Group C.

The results demonstrate that predicting the postoperative refraction in children under 1 years old is complex and factors such as age and laterality need to be considered.

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.